Akili Inc. is a digital therapeutics company that specializes in the development of video game-based treatments for cognitive disorders. The company is based in Boston, Massachusetts and was founded in 2011.
Akili's primary product is EndeavorRx, a prescription digital therapeutic game that is designed to improve attention function in children with attention deficit hyperactivity disorder (ADHD). The game is played on a mobile device and is designed to improve cognitive function by using game mechanics that are scientifically proven to enhance attention.
One of the key strengths of Akili is their focus on digital therapeutics. The company believes that digital therapeutics can help address the unmet medical needs of patients with cognitive disorders, and can provide an effective and accessible alternative to traditional therapies. This approach has allowed Akili to become a leader in the rapidly-evolving field of digital therapeutics.
In addition to their focus on digital therapeutics, Akili also places a strong emphasis on research and development. The company invests heavily in R&D, with a focus on developing new treatments and solutions that can address unmet medical needs in the cognitive disorder space. This approach has allowed Akili to stay at the forefront of the rapidly-evolving healthcare industry.
Financially, Akili is a privately held company and does not disclose financial information to the public.
Akili Inc. is a digital therapeutics company that is focused on the development of video game-based treatments for cognitive disorders. The company's focus on digital therapeutics, commitment to research and development, and innovative approach to healthcare make them an attractive partner for patients, healthcare providers, and investors seeking exposure to the digital health industry. With their extensive experience and investment in R&D, Akili is well-positioned to continue to develop innovative solutions that can improve the lives of patients with cognitive disorders.